What Do Medications Like Wegovy Actually Do? A Plain-English Explanation of GLP-1 Drugs

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 12 sources cited

Key Takeaways

• Wegovy and similar GLP-1 drugs mimic a natural gut hormone called GLP-1 (glucagon-like peptide-1) that your body releases after meals.
• They reduce appetite by acting on brain receptors in the hypothalamus, slow stomach emptying so you feel full longer, and improve insulin response in the pancreas.
• The combined effect is that patients eat 20% to 35% fewer calories per day on average without forcing it through willpower.
• In the STEP 1 trial, Wegovy produced 14.9% weight loss over 68 weeks versus 2.4% for placebo, and patients regain most of the weight after stopping unless they continue lifestyle changes.
• These drugs aren't shortcuts. They're appetite-regulation tools that work best alongside protein intake, strength training, and sustained habits.

Direct answer (40-60 words)

Wegovy and similar GLP-1 drugs mimic a natural gut hormone called GLP-1, which your body normally releases after eating. They reduce appetite by acting on the brain, slow stomach emptying so you feel full longer, and improve blood sugar control. The result is patients eat about 20% to 35% fewer calories per day.

Table of contents

1. The 30-second answer
2. What GLP-1 is in the body, and what it does naturally
3. How Wegovy mimics GLP-1, but better
4. The brain effect: why your appetite changes
5. The stomach effect: why you feel full longer
6. The pancreas effect: why blood sugar improves
7. The compound effect on calories and weight
8. What Wegovy doesn't do (clearing up myths)
9. What happens when you stop
10. Compounded semaglutide and how it relates
11. FAQ
12. Sources

What GLP-1 is in the body, and what it does naturally

GLP-1 (glucagon-like peptide-1) is a hormone your gut produces and releases into your bloodstream when you eat, especially after meals containing carbs and fat. The L-cells of your small intestine secrete it within minutes of food arriving.

In the body, natural GLP-1 has four main jobs:

1. Tell the pancreas to release insulin in response to glucose. This helps you handle the carbs you just ate.
2. Tell the pancreas to suppress glucagon. Glucagon raises blood sugar; suppressing it after a meal helps blood sugar normalize faster.
3. Slow gastric emptying. Food sits in the stomach a bit longer so glucose absorption is gradual rather than spiky.
4. Signal the brain to feel satisfied. GLP-1 receptors in the hypothalamus and brainstem register satiety and reduce further food intake.

These four functions evolved together. After a meal, GLP-1 is your body saying "you've eaten enough, slow down, manage the glucose load."

The catch: natural GLP-1 has a half-life of about 1 to 2 minutes in the bloodstream. The body breaks it down almost as fast as it releases it, by an enzyme called dipeptidyl peptidase-4 (DPP-4). So natural GLP-1 produces a brief signal, not a sustained one.

This rapid breakdown is one of the obesity puzzle pieces. People with obesity often have blunted GLP-1 responses to meals, meaning the satiety signal is weaker than it should be (Holst, Diabetologia 2019). The hormone is doing its job, but quietly.

How Wegovy mimics GLP-1, but better

Wegovy's active ingredient is semaglutide. Semaglutide is a GLP-1 analog: a slightly modified version of the natural hormone. The modifications do two things:

1. Resist DPP-4 breakdown. Semaglutide has chemical changes at specific positions that block the DPP-4 enzyme from cutting it.
2. Bind to albumin in the blood. A fatty acid chain attached to semaglutide lets it stick to albumin, the most abundant blood protein, which protects it from kidney clearance.

The result is a half-life of about 7 days for semaglutide, versus 1 to 2 minutes for natural GLP-1. One weekly injection produces a sustained GLP-1 receptor signal across the entire week, instead of the natural brief pulses that come and go with each meal.

This is the central insight: semaglutide doesn't do anything fundamentally new. It does what natural GLP-1 already does, but with sustained signaling instead of brief pulses. The same brain receptors, the same gut effects, the same pancreas response, just continuously rather than transiently.

This explains why the side effects look like an exaggerated version of normal post-meal physiology: feeling full sooner, slight nausea after eating, slower digestion. The medication is essentially extending the natural "I just ate" signal to all hours.

The brain effect: why your appetite changes

The most clinically powerful effect of Wegovy is in the brain. GLP-1 receptors are present in several brain regions involved in appetite regulation, especially:

• The arcuate nucleus of the hypothalamus, which integrates satiety signals
• The nucleus tractus solitarius in the brainstem, which processes vagal signals from the gut
• Areas associated with food reward and motivation, including parts of the limbic system

Functional MRI studies (van Bloemendaal et al., Diabetes 2014; Farr et al., Diabetologia 2016) show that semaglutide and similar GLP-1 drugs reduce activation in brain reward regions when participants view high-calorie foods. The neural "wanting" signal for food drops.

Patients describe this in remarkably consistent ways:

• "Food just isn't on my mind the way it was."
• "I forgot to eat lunch yesterday and it didn't bother me."
• "I can drive past my favorite bakery and not even think about it."
• "I get full at half my usual portion and the thought of more food is unappetizing."

This phenomenon, sometimes called "food noise" reduction, isn't a mystical effect. It's the predictable result of sustained GLP-1 receptor activation in the brain regions that previously demanded constant food attention.

The clinical significance is that calorie restriction stops feeling like willpower. Patients in the STEP trials reported eating an average of 24% fewer calories per day without conscious dieting (Friedrichsen et al., Diabetes Obes Metab 2021). The brain stopped asking for food as often.

The stomach effect: why you feel full longer

GLP-1 slows the rate at which the stomach empties food into the small intestine. Normal gastric emptying half-time (the time for half the meal to leave the stomach) is about 90 minutes. On a maintenance dose of semaglutide, this can extend to 3 to 4 hours, especially after fatty meals.

The practical effects:

• Smaller portions feel like full meals. A half-cup of food in a slow-emptying stomach signals fullness as effectively as a full cup did before.
• Hunger between meals is delayed. If breakfast is still emptying at 11 AM, your brain doesn't request lunch on the old schedule.
• You can lose track of when you last ate. This sounds odd to people who haven't experienced it, but is one of the most consistent patient reports.

The stomach effect is also responsible for some side effects. Slow gastric emptying can cause:

• Reflux when stomach contents back up against the lower esophageal sphincter
• Nausea when the stomach feels chronically full
• Constipation when the slowing extends down the GI tract
• Occasional vomiting if eating volume exceeds the slowed emptying rate

For more on managing these, see /articles/side-effects/glp1-gi-side-effects/.

The pancreas effect: why blood sugar improves

For patients with type 2 diabetes (the original indication for which semaglutide was developed and is sold as Ozempic), the pancreas effect is the main story.

Semaglutide does two things at the pancreas:

1. Glucose-dependent insulin release. When blood sugar rises after a meal, semaglutide amplifies the pancreas's insulin response. When blood sugar is normal or low, it doesn't push more insulin out (which is why GLP-1 drugs rarely cause hypoglycemia in non-diabetic patients).
2. Glucagon suppression. Glucagon raises blood sugar by signaling the liver to release stored glucose. Suppressing glucagon after a meal helps glucose return to baseline faster.

For non-diabetic weight loss patients, this effect is mostly an afterthought. Their blood sugar control is already adequate. But for the millions of patients with type 2 diabetes, glucose control is often the primary clinical goal, with weight loss being a beneficial secondary effect.

In the SUSTAIN trials of semaglutide for diabetes (Aroda et al., Lancet Diabetes Endocrinol 2018; Pratley et al., Lancet 2018), HbA1c reductions of 1.5% to 1.8% were typical, alongside 4 to 6 kg of weight loss.

The compound effect on calories and weight

When you put the brain, stomach, and pancreas effects together, you get the weight loss numbers seen in clinical trials.

The STEP 1 trial (Wilding et al., NEJM 2021):

• 1,961 adults with overweight or obesity, no diabetes
• Wegovy 2.4 mg weekly for 68 weeks
• Mean weight loss: 14.9%, versus 2.4% for placebo
• 86% of patients lost at least 5% of body weight
• 50% lost at least 15% of body weight

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022): for tirzepatide (Zepbound), a related drug that targets both GLP-1 and GIP receptors, weight loss reached 22.5% at the highest dose.

The mechanism behind these numbers: in published energy intake measurements (Friedrichsen et al., Diabetes Obes Metab 2021), patients on semaglutide consume 24% fewer calories per day, with the reduction concentrated in evening eating and snacking between meals. Hunger ratings drop, fullness ratings rise, and food preferences shift mildly toward less calorie-dense foods.

The cardiovascular benefits also matter. The SELECT trial (Lincoff et al., NEJM 2023) showed that semaglutide reduced major cardiovascular events by 20% in patients with overweight or obesity and pre-existing cardiovascular disease, even before considering the weight loss benefit.

What Wegovy doesn't do (clearing up myths)

A handful of common misconceptions show up in patient discussions, including on Reddit:

It doesn't burn fat directly. Wegovy doesn't go to your fat cells and break them down. It reduces appetite, you eat less, you go into calorie deficit, and your body uses stored fat for energy. The drug is the cause of the calorie deficit, not the fat loss itself.

It doesn't change your metabolism long-term in a magical way. When you lose weight, basal metabolic rate falls modestly because there's less body to maintain (this is true for any weight loss). Wegovy doesn't reverse this. It does, however, suppress appetite enough that you can sustain the necessary deficit at the lower body weight.

It's not a cleanse or detox. It doesn't flush anything out of your body. The slowed gastric emptying is the opposite of a cleanse, in fact.

It doesn't make you immune to overeating. You can eat past the satiety signal if you really try. Most patients find this unpleasant (because the slowed emptying makes overeating uncomfortable), but it's possible.

It's not addictive in the substance-use sense. Stopping doesn't cause withdrawal. The downside of stopping is that the appetite suppression goes away and most patients regain weight if they don't have new habits in place.

It doesn't preserve muscle mass on its own. About 25% to 35% of weight lost on GLP-1 drugs is lean tissue, similar to weight loss from any calorie deficit. Strength training and adequate protein intake are needed to bias the loss toward fat.

What happens when you stop

The STEP 4 trial (Rubino et al., JAMA 2021) is the cleanest answer to this question. Patients who lost weight on semaglutide for 20 weeks were then randomized to continue or switch to placebo. Over the next 48 weeks:

• Patients who continued: kept losing weight, ending at about 17.4% total weight loss
• Patients who switched to placebo: regained an average of 6.9% of body weight, ending at about 5.0% total weight loss

The pattern was consistent: stopping the medication reverses about two-thirds of the weight loss within a year, unless patients have established sustained changes in eating, activity, and food environment that maintain the lower calorie intake on their own.

The clinical implication is that Wegovy is generally a long-term medication for chronic weight management, similar to how blood pressure or cholesterol medications are long-term. It's not a 6-month fix. Discontinuation should be planned with a provider, not abrupt.

For more on stopping treatment, see /articles/stopping-treatment/glp1-stopping-protocol/.

Compounded semaglutide and how it relates

Compounded semaglutide is prepared by state-licensed compounding pharmacies in response to individual prescriptions. The active ingredient is the same semaglutide molecule used in Wegovy.

A few clinical points:

• The mechanism in the body is identical. Same brain effect, same stomach effect, same pancreas effect.
• Compounded medications are not FDA-approved and have not undergone the same review process as FDA-approved drugs.
• Compounded medications are not interchangeable with brand-name products.
• Reliable compounding pharmacies use USP-grade semaglutide sodium and follow USP 797 sterile compounding standards.

For more on the compounded option and how to evaluate it, see /articles/compounded-and-peptides/compounded-semaglutide-overview/.

FAQ

What does Wegovy do to your body? Wegovy mimics a natural gut hormone called GLP-1. It reduces appetite by acting on brain receptors, slows stomach emptying so you feel full longer, and improves how the pancreas responds to glucose. The combined effect is that patients eat 20% to 35% fewer calories per day.

How does Wegovy make you lose weight? By reducing appetite enough that you naturally eat less, without conscious dieting. The brain stops requesting food as often, and full feelings come at smaller meal sizes. Over weeks, this calorie deficit causes your body to use stored fat for energy.

Is Wegovy actually a hormone? Wegovy contains semaglutide, which is a synthetic analog of the natural hormone GLP-1. It's chemically very similar to your own GLP-1 but engineered to last about 7 days in the bloodstream instead of 1 to 2 minutes.

Why do I lose food noise on Wegovy? GLP-1 receptors in brain regions involved in food reward and motivation get sustained activation on Wegovy. Imaging studies show reduced brain activity in these regions when patients view high-calorie foods. The mental "wanting" of food drops noticeably.

What's the difference between Wegovy and Ozempic? Both contain semaglutide. Wegovy is FDA-approved for chronic weight management at doses up to 2.4 mg weekly. Ozempic is FDA-approved for type 2 diabetes at doses up to 2.0 mg weekly. The drug is the same; the indication and maximum dose differ.

Does Wegovy permanently change your metabolism? No, not in a magical way. Like any weight loss, basal metabolic rate falls slightly because you have less body mass to maintain. Wegovy doesn't reverse this, but it does suppress appetite enough to sustain the lower calorie intake needed at the new weight.

Can Wegovy cause weight gain after stopping? Yes, often. The STEP 4 trial showed patients who stopped semaglutide regained about two-thirds of the lost weight within a year. The drug suppressed appetite while taken; once stopped, baseline appetite returns and patients tend to eat more.

Is Wegovy a steroid or stimulant? Neither. Wegovy is a peptide hormone analog, in the same general drug class as insulin or thyroid hormone replacement. It doesn't have the metabolism-boosting effects of stimulants or the muscle-building effects of steroids.

Why does Wegovy cause nausea? Slowed gastric emptying makes the stomach feel chronically fuller, which the brain registers as mild to moderate nausea, especially during dose increases. Nausea typically peaks within 7 to 14 days of a dose change and improves as the body adapts.

Can Wegovy fail to work? About 14% of patients in the STEP 1 trial lost less than 5% of body weight. Reasons include genetic variation in receptor sensitivity, inadequate dose titration, low adherence, and high baseline calorie intake. Patients who don't respond after 16 weeks at the maximum dose typically don't respond with longer treatment.

Does Wegovy work for everyone? No. Response is bell-curve distributed. About 50% of patients lose more than 15% of body weight, 30% lose 5% to 15%, and 14% lose less than 5%. Individual variation in receptor sensitivity, adherence, and lifestyle all contribute.

Is Wegovy safe long-term? The longest published follow-up is from the SELECT trial (over 4 years, with 17,604 patients), which showed cardiovascular benefit and a manageable safety profile. There's no signal of catastrophic long-term harm. The medication is generally taken indefinitely for sustained weight management.

Sources

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
3. Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325:1414-1425.
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
5. Holst JJ. The physiology of glucagon-like peptide 1. Diabetologia. 2019;62:7-21.
6. van Bloemendaal L, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas. Diabetes. 2014;63:4186-4196.
7. Farr OM, et al. Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these alterations are associated with activity changes in the hypothalamus. Diabetologia. 2016;59:954-965.
8. Friedrichsen M, et al. The effect of semaglutide on energy intake, appetite, control of eating and gastric emptying. Diabetes Obes Metab. 2021;23:754-762.
9. Aroda VR, et al. Effect of subcutaneous semaglutide vs placebo as add-on to basal insulin (SUSTAIN 5). Lancet Diabetes Endocrinol. 2018;6:610-620.
10. Pratley R, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinol. 2018;6:275-286.
11. Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984.
12. FDA labeling for Wegovy (semaglutide) injection. Updated 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.